Strong survival data set stage for first-half Abraxane filings in pancreatic cancer
This article was originally published in Scrip
Executive Summary
Celgene will present further details of its Phase III MPACT trial with Abraxane later this week, showing that the nanoparticle albumin-bound formulation of paclitaxel added to gemcitabine significantly improved overall survival - and doubled two-year survival - over gemcitabine alone in the first-line treatment of advanced pancreatic cancer.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.